Consequently and please now turn to the next slide, we have decided to sharpen our focus on what we do best, which is sourcing cutting-edge science and cost effectively developing patented seed ...

Reports Q2 revenue $106.7M vs. $140.2M last year. Mr. Federico Trucco, Bioceres (BIOX)’ Chief Executive Officer, commented: “Calendar year 2024 ...

Korea supports 12 university research institutes with 1 billion won each annually Korea aims to enhance university research ...

Breast cancers at all stages are defined by the structure of their genomes, researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.

Bioceres Crop Solutions Corp. (Bioceres) (NASDAQ: BIOX), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ...

PureHealth achieved a 58% year-on-year increase in revenue to AED 25.8 billion in FY-2024, reflecting a combination of strong ...

Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

Bioceres Crop Solutions Corp (NASDAQ:BIOX) is set to release its Q2 2025 earnings on Feb 12, 2025. The consensus estimate for Q2 2025 revenue is $129.50 million, and the earnings are expected to ...

Bio X Cell, the world's leading provider of functional antibodies for translational research, is strengthening its global ...

By establishing a stronger regional presence in APAC, Bio X Cell aims to better support its customers in one of the world's most dynamic and rapidly growing biomedical research markets.

The proceeds will allow the company to deliver full results from BIRCH, its Phase 2a trial of BIOX-101 to treat intracerebral hemorrhage (ICH), an orphan disease with no currently approved ...

By establishing a stronger regional presence in APAC, Bio X Cell aims to better support its customers in one of the world's most dynamic and rapidly growing biomedical research markets. "This new ...